Promising drug combo targets aggressive brain cancers in youth
NCT ID NCT07644312
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given after radiation therapy. The study will enroll 12 participants and monitor side effects and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could a parasite drug fight childhood brain tumors?
- Could an antiparasitic drug boost radiation against childhood brain tumors?